PHARMAC is seeking feedback on a proposed change to the funding of lamotrigine dispersible tablets used in the treatment of epilepsy and/or bipolar disorder:
- the funded brands of lamotrigine 25 mg, 50 mg and 100 mg dispersible tablets would reduce from current three funded brands (Lamictal, Arrow-Lamotrigine and Logem) to just one funded brand (Logem), following a transition period;
- from 1 May 2019, Logem would be the only funded brand of lamotrigine 25 mg, 50 mg and 100 mg dispersible tablets in both the community and hospital settings.
There is no proposed change to the listing of lamotrigine 2 mg (Lamictal) and 5 mg (Lamictal, Arrow-Lamotrigine) dispersible tablets, which would remain listed and fully funded.
Consultation closes at 4 pm on Wednesday, 26 September 2018 and feedback can be emailed to email@example.com.